Takeaway
- Gout is common in patients with HIV and co-existence of hypertension is a major risk factor associated with a 4-fold increased risk for gout.
- Use of nucleoside reverse transcriptase inhibitors (NNRTIs) was associated with a 70% reduction in the risk for gout.
Why this matters
- Currently, there are limited data specifically on gout in people living with HIV.
- Findings may highlight an area of interest for future research.
Study design
- This case-control study identified 45 patients diagnosed with gout and 90 age-matched control group and explored the prevalence of and risk factors for gout in patients with HIV.
- Funding: None disclosed.
Key results
- The estimated point prevalence of gout was 2.2% (95% CI, 1.6%-2.9%).
- All of the cases identified were men (mean age, 56 years; white Caucasian, 84%; black African, 9%).
- Cases were more non-Caucasians and on average 10.5 kg heavier vs control group (8.9% vs 4.4%; P=.02 and 88 kg vs 77.5 kg; P<.001, respectively).
- The risk for gout was significantly associated with a diagnosis of hypertension (OR, 4.8; 95% CI, 1.8-12.4).
- No association was seen between individual drug or anti-retroviral therapy class with the risk of developing gout.
- Ever exposure to NNRTIs was associated with reduced risk for gout (OR, 0.3; 95% CI, 0.12-0.88).
Limitations
- Possibility of underestimation of true point prevalence.
References
References
